291 related articles for article (PubMed ID: 31462263)
21. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
[TBL] [Abstract][Full Text] [Related]
22. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
Kridin K; Ahmed AR
Autoimmun Rev; 2020 Mar; 19(3):102466. PubMed ID: 31917267
[TBL] [Abstract][Full Text] [Related]
23. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections.
Langer-Gould A; Li BH; Smith JB; Xu S
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200211. PubMed ID: 38507657
[TBL] [Abstract][Full Text] [Related]
24. The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome.
Inoki Y; Nishi K; Sato M; Ogura M; Kamei K
Pediatr Nephrol; 2023 Feb; 38(2):451-460. PubMed ID: 35748947
[TBL] [Abstract][Full Text] [Related]
25. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.
Sacco KA; Abraham RS
Immunotherapy; 2018 Jun; 10(8):713-728. PubMed ID: 29569510
[TBL] [Abstract][Full Text] [Related]
26. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
Tambralli A; Beukelman T; Cron RQ; Stoll ML
J Rheumatol; 2015 Mar; 42(3):541-6. PubMed ID: 25593242
[TBL] [Abstract][Full Text] [Related]
28. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
29. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia.
Caballero-Ávila M; Álvarez-Velasco R; Moga E; Rojas-Garcia R; Turon-Sans J; Querol L; Olivé M; Reyes-Leiva D; Illa I; Gallardo E; Cortés-Vicente E
Neuromuscul Disord; 2022 Aug; 32(8):664-671. PubMed ID: 35811274
[TBL] [Abstract][Full Text] [Related]
30. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.
Marco H; Smith RM; Jones RB; Guerry MJ; Catapano F; Burns S; Chaudhry AN; Smith KG; Jayne DR
BMC Musculoskelet Disord; 2014 May; 15():178. PubMed ID: 24884562
[TBL] [Abstract][Full Text] [Related]
31. Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab.
Filanovsky K; Miller EB; Sigler E; Berrebi A; Shvidel L
Recent Pat Anticancer Drug Discov; 2016; 11(2):228-35. PubMed ID: 26825174
[TBL] [Abstract][Full Text] [Related]
32. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
[TBL] [Abstract][Full Text] [Related]
33. Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT.
Luterbacher F; Bernard F; Baleydier F; Ranza E; Jandus P; Blanchard-Rohner G
Front Immunol; 2021; 12():773853. PubMed ID: 35003091
[TBL] [Abstract][Full Text] [Related]
34. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.
Christou EAA; Giardino G; Worth A; Ladomenou F
Int Rev Immunol; 2017 Nov; 36(6):352-359. PubMed ID: 28800262
[TBL] [Abstract][Full Text] [Related]
35. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
Casulo C; Maragulia J; Zelenetz AD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):106-11. PubMed ID: 23276889
[TBL] [Abstract][Full Text] [Related]
36. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
37. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
Delbe-Bertin L; Aoun B; Tudorache E; Lapillone H; Ulinski T
Pediatr Nephrol; 2013 Mar; 28(3):447-51. PubMed ID: 23212560
[TBL] [Abstract][Full Text] [Related]
38. Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.
Mizuhara K; Fujii N; Meguri Y; Takahashi T; Aoe M; Nakamura M; Seike K; Sando Y; Fujii K; Abe M; Sumii Y; Urata T; Fujiwara Y; Saeki K; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Maeda Y
Int J Hematol; 2020 Sep; 112(3):422-426. PubMed ID: 32342335
[TBL] [Abstract][Full Text] [Related]
39. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
Reis J; Aguiar F; Brito I
Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
[TBL] [Abstract][Full Text] [Related]
40. Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases.
Avouac A; Maarouf A; Stellmann JP; Rico A; Boutiere C; Demortiere S; Marignier R; Pelletier J; Audoin B
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33722933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
